Jiangsu Hengrui Medicine saw the highest growth of 1.59% in patent filings in May and 2.16% in grants in April in Q2 2024. Compared to Q1 2024, Q2 2024 saw an increase in patent filings by 0.46% and grants by 2.16%. GlobalData’s DataBook provides a comprehensive analysis of Jiangsu Hengrui Medicine‘s patent filings and grants. Buy the databook here.
Jiangsu Hengrui Medicine has been focused on protecting inventions in China(CN) with 43 publications in Q2 2024
The China(CN) Patent Office dominates the patent filings and grants with nearly 37% filings and 83% grants. The China(CN), World Intellectual Property Organization(WIPO), European Patent Office(EPO), and South Korea(KR) patent Office are among the top ten patent offices where Jiangsu Hengrui Medicine is filings its patents. Among the top granted patent authorities, Jiangsu Hengrui Medicine has 83% of its grants in China(CN), 4% in European Patent Office(EPO) and 4% in Australia(AU).
Roche and Johnson & Johnson could be the strongest competitors for Jiangsu Hengrui Medicine
Patents related to climate change and nanomedicine lead Jiangsu Hengrui Medicine's portfolio
Jiangsu Hengrui Medicine has the highest number of patents in climate change followed by, nanomedicine and rare diseases. For climate change, nearly 33% of patents were filed and 80% of patents were granted in Q2 2024.
Manufacturing/industrial related patents lead Jiangsu Hengrui Medicine portfolio followed by osteoporosis, and pancreatic cancer
Jiangsu Hengrui Medicine has highest number of patents in manufacturing/industrial followed by osteoporosis, pancreatic cancer, pain, and non-small cell lung cancer.
For comprehensive analysis of Jiangsu Hengrui Medicine's filings and grants, buy the databook here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.